- Home
- PRTG vs OVID Comparison
PRTG vs OVID Comparison
Compare PRTG & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- OVID
- Stock Information
- Founded
- PRTG 1973
- OVID 2014
- Country
- PRTG British Virgin Islands
- OVID United States
- Employees
- PRTG N/A
- OVID N/A
- Industry
- PRTG Oil & Gas Production
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- PRTG Energy
- OVID Health Care
- Exchange
- PRTG Nasdaq
- OVID Nasdaq
- Market Cap
- PRTG 17.7M
- OVID 20.6M
- IPO Year
- PRTG N/A
- OVID 2017
- Fundamental
- Price
- PRTG $8.45
- OVID $0.91
- Analyst Decision
- PRTG
- OVID Strong Buy
- Analyst Count
- PRTG 0
- OVID 4
- Target Price
- PRTG N/A
- OVID $3.13
- AVG Volume (30 Days)
- PRTG 45.9K
- OVID 1.7M
- Earning Date
- PRTG 08-26-2025
- OVID 08-13-2025
- Dividend Yield
- PRTG N/A
- OVID N/A
- EPS Growth
- PRTG N/A
- OVID N/A
- EPS
- PRTG N/A
- OVID N/A
- Revenue
- PRTG N/A
- OVID $6,651,000.00
- Revenue This Year
- PRTG N/A
- OVID N/A
- Revenue Next Year
- PRTG N/A
- OVID $5.32
- P/E Ratio
- PRTG N/A
- OVID N/A
- Revenue Growth
- PRTG N/A
- OVID 1070.95
- 52 Week Low
- PRTG $2.21
- OVID $0.24
- 52 Week High
- PRTG $23.01
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- PRTG 60.06
- OVID 76.81
- Support Level
- PRTG $8.22
- OVID $0.48
- Resistance Level
- PRTG $9.30
- OVID $1.02
- Average True Range (ATR)
- PRTG 0.96
- OVID 0.08
- MACD
- PRTG 0.15
- OVID 0.04
- Stochastic Oscillator
- PRTG 63.84
- OVID 83.49
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.